Elequin Capital’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Elequin Capital’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300	Closed	-$3.03K	–	673
2022 Q4	$3.03K	Hold	300	–	–	﹤0.01%	561
2022 Q3	$3K	Buy	+300	New	+$2.96K	﹤0.01%	466

Elequin Capital's EBAC Position: Q1 2023 in Review

Elequin Capital sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 300 shares — an estimated $3.03K sold.

Elequin Capital first reported a position in EBAC in Q3 2022 and held it in 2 quarters. The position peaked at $3.03K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Elequin Capital reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Elequin Capital sold 300 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $3.03K.
Elequin Capital first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 2 quarters.
Elequin Capital's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $3.03K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Elequin Capital's 13F filing for Q1 2023, filed 11 May 2023.